E Coli Vaccine Poultry

Colibacillosis, an infection in poultry caused by avian pathogenic Escherichia coli, is one of the two main causes of mortality and morbidity in poultry farms worldwide. As the world’s second-largest poultry producer, Brazil is particularly affected by E. coli.

Antibiotics are used to prevent and treat the infection, but they have little effect on multi-resistant E. coli strains. Vaccination has the potential to provide effective protection by inducing an immune response, thus reducing the number of infections and the subsequent use of antibiotics.


Escherichia coli (E. coli) is a commensal bacterium in the intestines of chickens. However, some strains, including extra-intestinal avian pathogenic E. coli (APEC), may cause invasive infections outside the intestine, namely colibacillosis This disease is responsible for significant economic losses in the poultry industry worldwide due to reduced production, high treatment costs, rejection of carcasses, and mortality APEC exaggerates the severity and complications of Avian Influenza (AI) H9N2, Infectious Bronchitis Virus (IBV) and Velogenic Viscerotropic Newcastle Disease (VVND) endemic to ME and increases post-vaccination reactions associated with spray vaccination, particularly to the Newcastle Disease Virus (NDV) LaSota vaccine and variants of IBV vaccine strains.

Antibiotic therapy is used to control this infection; however, there is a significant increase in drug-resistant strains of E. coli. Restrictions on the use of antibiotics by the European Union and a reduction in the number of new active ingredients entering the market have been limiting therapeutic effectiveness. Medication for broiler chicks of the first three days of age in ME countries is common in eliminating vertical or hatchery-transmitted bacterial pathogens

Features of E Coli Vaccine Poultry

It’s impossible to stop all the factors that cause colibacillosis. But with Poulvac® E. coli, the only commercially available modified-live Escherichia coli (E. coli) vaccine, it is possible to help protect against both the disease and productivity loss.

Poulvac E. coli is recommended for mass administration to healthy chickens and turkeys 1 day of age or older. It’s the only modified-live E. coli vaccine available that’s demonstrated to be safe for birds in helping protect U.S. poultry operations against this costly threat. The product has demonstrated to help improve bird health in all major segments of commercial poultry production:

  • Broilers
  • Layers
  • Breeders
  • Turkeys


Commercial NameCompanyCountryTarget SpeciesStrainCompositionCommentsImageLabel
Nobilis E.Coli inacMSD AHThe NetherlandsChickens (Broiler breeders)Fimbrial antigen (F11)Flagellar antigen (FT)F11: 100 μgFT: 100 μgWater-in-oil emulsion
Coli-Ave OleosaBiovetBrazilChickens (breeders, layers)O1, O2 , O35 and O78Water-in-oil emulsion
Avian Escherichia Coli vaccineQingdao Yebio BioengineeringChinaChickens (Broiler breeders)15*108.0 viable cells/ml
Izovac ColiVaxxinova (Izo)ItalyChickens (Broiler breeders)E. Coli serotypes 01, 02, 078109.0 CFU/EachWater-in-oil emulsion

Prices of E Coli Vaccine Poultry

$34.95 – $146.72

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.